1. Home
  2. RVYL vs ENSC Comparison

RVYL vs ENSC Comparison

Compare RVYL & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVYL
  • ENSC
  • Stock Information
  • Founded
  • RVYL 2007
  • ENSC 2003
  • Country
  • RVYL United States
  • ENSC United States
  • Employees
  • RVYL N/A
  • ENSC N/A
  • Industry
  • RVYL Professional Services
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVYL Consumer Discretionary
  • ENSC Health Care
  • Exchange
  • RVYL Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • RVYL 8.4M
  • ENSC 9.5M
  • IPO Year
  • RVYL N/A
  • ENSC N/A
  • Fundamental
  • Price
  • RVYL $1.40
  • ENSC $6.07
  • Analyst Decision
  • RVYL Hold
  • ENSC
  • Analyst Count
  • RVYL 1
  • ENSC 0
  • Target Price
  • RVYL N/A
  • ENSC N/A
  • AVG Volume (30 Days)
  • RVYL 163.3K
  • ENSC 154.9K
  • Earning Date
  • RVYL 11-14-2024
  • ENSC 11-12-2024
  • Dividend Yield
  • RVYL N/A
  • ENSC N/A
  • EPS Growth
  • RVYL N/A
  • ENSC N/A
  • EPS
  • RVYL N/A
  • ENSC N/A
  • Revenue
  • RVYL $63,529,000.00
  • ENSC $4,421,404.00
  • Revenue This Year
  • RVYL N/A
  • ENSC N/A
  • Revenue Next Year
  • RVYL $48.92
  • ENSC N/A
  • P/E Ratio
  • RVYL N/A
  • ENSC N/A
  • Revenue Growth
  • RVYL 16.09
  • ENSC 40.41
  • 52 Week Low
  • RVYL $0.89
  • ENSC $2.12
  • 52 Week High
  • RVYL $5.48
  • ENSC $30.90
  • Technical
  • Relative Strength Index (RSI)
  • RVYL 45.89
  • ENSC 42.77
  • Support Level
  • RVYL $1.37
  • ENSC $5.34
  • Resistance Level
  • RVYL $1.65
  • ENSC $8.27
  • Average True Range (ATR)
  • RVYL 0.20
  • ENSC 1.06
  • MACD
  • RVYL -0.00
  • ENSC -0.24
  • Stochastic Oscillator
  • RVYL 18.97
  • ENSC 18.43

About RVYL Ryvyl Inc.

Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: